Study details
Enrolling now
Viral Mucosal Reprogramming Trial
The University of Texas Medical Branch, Galveston
NCT IDNCT05331170ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
75
Study length
about 4 years
Ages
18–60
Locations
1 site in TX
What this study is about
Researchers are testing a treatment called RG-RV to see how it affects the airways in people with allergies and healthy individuals. The treatment involves an injection of RG-RV16 into the nasal passages. The trial will last for 1465 days.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Receive Research Grade RG-RV
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Standard
How treatment is administered
Treatment Assignment
All receive treatment
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Endpoints
Primary: PD-L1 Expression
Secondary: URI Cold Symptoms
Body systems
Respiratory